ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX)"

  • Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting

    At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials

    René-Marc Flipo1, Alain Saraux2, Christophe Hudry3, Cécile Gaujoux-Viala4, Eric Senbel5, Sonia Tropé6, Elena Zinovieva7, Agnès Courbeyrette8 and Hélène Herman-Demars7, 1Hôpital Roger Salengro, Lille, France, 2Rheumatology, CHU Brest, Brest, France, 3AP-HP Hôpital Cochin, Paris, France, 4Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, 5Rheumatology office, Marseille, France, 6149 avenue du Maine, ANDAR, Paris, France, 7Medical Department Nordic Pharma, Paris, France, 8Medical Departement, Nordic Pharma, Paris, France

    Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
  • Abstract Number: 2446 • 2018 ACR/ARHP Annual Meeting

    The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate

    Sho Sasaki1, Yasushi Kondo2, Yasuo Suzuki3, Takayoshi Kurabayashi1, Yasushi Koyama1, Yuto Izumi1, Yoko Nakagome1, Kazuki Hirano1, Chiho Yamada1 and Shinji Sato1, 1Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, 2Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Tokai University Hachioji Hospital, Hachioji, Japan, Isehara, Japan

    Background/Purpose: Lymphoproliferative disorders (LPDs) are a serious complication in patients with rheumatoid arthritis (RA). Methotrexate (MTX) is known to be able to cause a development…
  • Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting

    Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

    Yoko Shimizu1, Eiichi Tanaka1, Eisuke Inoue1,2, Kumiko Saka1, Eri Sugano1, Naohiro Sugitani1,3, Moeko Ochiai1, Rei Yamaguchi1, Naoki Sugimoto1, Ayako Nakajima1,3, Katsunori Ikari1, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
  • Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting

    Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry

    Jeffrey R. Curtis1, J. Lynn Palmer2, George W. Reed3, Jeffrey Greenberg4, Dimitrios A. Pappas5, Leslie R Harrold6 and Joel Kremer4, 1University of Alabama at Birmingham, Birmingham, AL, 2Corrona Research Foundation, Albany, NY, 3UMass Medical School, Worcester, MA, 4Corrona LLC, Waltham, MA, 5Columbia University, New York, NY, 6University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
  • Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting

    Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?

    René-Marc Flipo1, Eric Senbel2, Sonia Tropé3, Elena Zinovieva4, Agnès Courbeyrette5 and Hélène Herman-Demars4, 1Hôpital Roger Salengro, Lille, France, 2Rheumatology office, Marseille, France, 3149 avenue du Maine, ANDAR, Paris, France, 4Medical Department Nordic Pharma, Paris, France, 5Medical Departement, Nordic Pharma, Paris, France

    Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…
  • Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting

    Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis

    Christopher T. Ritchlin1, Joseph F. Merola2, Amanda M. Gellett3, Chen-Yen Lin3 and Talia Muram3, 1University of Rochester Medical Center, Rochester, NY, 2Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
  • Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting

    Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Michael D. George1, Joshua Baker2 and Alexis Ogdie3, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
  • Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting

    Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Alexis Ogdie1, Mei Liu2, Meghan Glynn2, Kelechi Emeanuru2, Leslie R Harrold3, Sven Richter4, Benoit Guerette4 and Philip J. Mease5, 1University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Celgene Corporation, Summit, NJ, 5Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
  • Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate

    Tsutomu Takeuchi1, Yoshiya Tanaka2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Mitsuhiro Rokuda6, Hiroyuki Izutsu6, Satoshi Ushijima6, Yuichiro Kaneko6, Teruaki Shiomi6 and Emi Yamada6, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Nagasaki University, Nagasaki, Japan, 4University of Tokyo, Tokyo, Japan, 5Yokohama City University, Yokohama, Japan, 6Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
  • Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting

    Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients

    Madeline J. Epsten1, Lisa A. Mandl1, Jackie Szymonifka2 and Sergio Schwartzman1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY

    Background/Purpose:  There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
  • Abstract Number: 959 • 2018 ACR/ARHP Annual Meeting

    The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System

    Elizabeth Pahomov1, Yuliya Belopolsky1, Arshad Ali1 and Robert Woodrick2, 1Internal Medicine, NorthShore University HealthSystem, Evanston, IL, 2Rheumatology, NorthShore University HealthSystem, Evanston, IL

    Background/Purpose: MTX has become the cornerstone in treatment of many rheumatologic disorders including rheumatoid arthritis and psoriasis. Although MTX can have a profound impact on…
  • Abstract Number: 2819 • 2018 ACR/ARHP Annual Meeting

    Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis

    Isaac Smith1, Jie Wei2, Yuqing Zhang3, Hyon K. Choi2 and Marcy Bolster1, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, 3Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of premature cardiovascular events and mortality. Prospective general population studies have shown moderate alcohol consumption…
  • Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with  Methotrexate

    Giorgia Martini1, Gloria Fadanelli1, Anna Agazzi1, Fabio Vittadello1, Alessandra Meneghel2 and Francesco Zulian2, 1Department of Woman and Child Health, University of Padua, Padua, Italy, 2University of Padua, Department of Woman and Child Health, Padua, Italy

    Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…
  • Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting

    High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis

    Philippe Carron1, Gaëlle Varkas2, Thomas Renson3, Roos Colman4, Dirk Elewaut5 and Filip van Den Bosch6, 1Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, 2Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, 3Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, 4Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, 5Ghent University Hospital and VIB Ghent University, Ghent, Belgium, 6Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium

    Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…
  • Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting

    Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches

    Helga Westerlind1, Mateusz Maciejewski2, Thomas Frisell3, Scott Jelinsky4, Daniel Ziemek5 and Johan Askling1, 1Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Systems Immunology, Inflammation & Immunology,, Pfizer, Cambridge, MA, 3Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 4Inflammation and Immunology, Pfizer Research and Development, Cambridge, MA, 5Systems Immunology, Inflammation & Immunology,, Pfizer, Berlin, Germany

    Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology